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Abstract   84 
Background 85 
Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, 86 
many patients suffer or have suffered from other diseases. Identifying disease-patterns 87 
associated with PDAC risk may enable a better characterization of high-risk patients.  88 
Methods    89 
Multimorbidity patterns (MPs) were assessed from 17 self-reported conditions using hierarchical 90 
clustering, principal component, and factor analyses in 1705 PDAC cases and 1084 controls from 91 
a European population. Their association with PDAC was evaluated using adjusted logistic 92 
regression models. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was 93 
stratified into recent (<3 years) and long-term (>3 years). The MPs and PDAC genetic networks 94 
were explored with DisGeNET bioinformatics-tool which focuses on gene-diseases associations 95 
available in curated databases. 96 
Results 97 
Three MPs were observed: gastric (heartburn, acid regurgitation, H. pylori infection, and ulcer), 98 
metabolic syndrome (obesity, type-2 diabetes, hypercholesterolemia, and hypertension), and 99 
atopic (nasal allergies, skin allergies, and asthma). Strong associations with PDAC were 100 
observed for ≥2 recently diagnosed gastric conditions (odds ratio [OR], 6.13; 95%CI 3.01-12.5) 101 
and for ≥3 recently diagnosed metabolic syndrome conditions (OR, 1.61; 95%CI 1.11-2.35). 102 
Atopic conditions were negatively associated with PDAC (high adherence score OR for tertile III, 103 
0.45; 95%CI 0.36 – 0.55). Combining type-2 diabetes with gastric MP resulted in higher PDAC 104 
risk for recent (OR, 7.89; 95%CI 3.9-16.1) and long-term diagnosed conditions (OR, 1.86; 95%CI 105 
1.29-2.67). A common genetic basis between MPs and PDAC was observed in the bioinformatics 106 
analysis.  107 
Conclusions  108 
Specific multimorbidities aggregate and associate with PDAC in a time-dependent manner. A 109 
better characterization of a high-risk population for PDAC may help in the early diagnosis of this 110 
cancer. The common genetic basis between MP and PDAC points to a mechanistic link between 111 
these conditions. 112 
 113 
Keywords 114 
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Key Message (400characters max (spaces included)= 397) 116 
We explored the co-occurrence of morbidities and their common effect on pancreatic cancer. We 117 
showed that some groups of morbidities cluster together. Given that multimorbidity is frequent in 118 
the adult population, evaluating the collective effect of patterns of conditions will allow a better 119 
characterization of risk for this malignancy potentially improving the management of affected 120 
patients.  121 
122 
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Introduction 123 
Pancreatic ductal adenocarcinoma (PDAC) is a dreadful disease usually diagnosed in late 124 
adulthood; hence, many patients suffer from other diseases [1,2]. PDAC patients present certain 125 
morbidities more often than non-PDAC patients, including chronic pancreatitis, type two diabetes 126 
mellitus (T2DM) or obesity [3–5]. Few studies focus in constellations of morbidities, and most 127 
explore associations between individual conditions and PDAC risk. In PDAC, multimorbidity has 128 
been mainly studied in the context of the metabolic syndrome (MetS), a cluster of conditions 129 
including abdominal obesity, hypertension, fasting hyperglycemia and serum 130 
hypertriglyceridemia, and low HDL cholesterol [6]. Having >3 MetS conditions has been 131 
associated with a 2-fold increased PDAC risk [7] yet, few studies have characterized in detail this 132 
relationship [8–12]. Additional multimorbidity patterns (MPs) affecting PDAC might exist, providing 133 
key information on disease mechanisms and contributing to the development of strategies to 134 
improve risk assessment. 135 
We explored the patterns of co-occurrence of 17 self-reported medical conditions and 136 
their association with PDAC in a European case-control population. Identifying MPs and 137 
evaluating their effect on PDAC risk provides clues on common (genetic and/or environmental) 138 
backgrounds and allow us to obtain a finer characterization of risk. The assessment of time since 139 
diagnosis of these conditions allowed us to evaluate whether the morbidities represent a risk 140 
factor or an early manifestation of the malignancy.  141 
 142 
Methods 143 
Study population 144 
The PanGenEU case-control study recruited PDAC patients >18 years old from Spain, United 145 
Kingdom, Germany, Ireland, Italy, and Sweden between 2009 and 2014 (Supplementary Annex 146 
S1, Table S2). Italy contributed with cases only. Controls were hospital-based, except in Ireland 147 
and Sweden where controls were population-based. Controls had no history of PDAC and 148 
principal diagnosis at admission was unrelated to known risk factors of PDAC (Supplementary 149 
Table S1). Response rate was  86.3% in cases and 77.8% in controls. IRB approval and written 150 
informed consent were obtained from all centers and participants. 151 
Health monitors performed in-person interviews; subjects answered “yes/no” to “Has your 152 
doctor ever told you that you had any of the following illnesses, health problems or procedures?” 153 
for 25 medical conditions (Supplementary TableS3). Obesity (Body mass index, BMI >30 kg/m2) 154 
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was calculated using reported usual adult height and weight two years before recruitment. Only 155 
conditions with prevalence >2% were considered. Subjects without information in the medical 156 
questions  were removed (n=268, 8.8%), leaving 1705 cases and 1084 controls. Age, sex and 157 
smoking were not statistically different between included and excluded subjects (p-value >0.05).  158 
 159 
Statistical analysis   160 
Data was imputed using missForest R package (Supplementary Methods). Adjustment variables 161 
were selected using the 10% change of estimate method. Statistical significance was considered 162 
as p-value <0.05. Analyses were performed using R version 3.1.2. 163 
All combinations of two (comorbidity) and three morbidities (trimorbidity) within an 164 
individual were considered (Supplementary Methods). MPs were defined separately for cases 165 
and controls using hierarchical cluster analysis, principal component (PCA), and factor (FA) 166 
analyses (Supplementary Methods). Variables were created by combining presence/absence of 167 
conditions (0=none, 1=any one, 2=any two, 3=any three or more) for gastric (H. pylori, acid 168 
regurgitation, heartburn and ulcer), MetS (T2D, hypertension, obesity and hypercholesterolemia), 169 
and atopic (asthma, nasal and skin allergies) patterns. To determine the degree of a subject 170 
belonging to the identified patterns, i.e. adherence to a pattern, factor scores were calculated: low 171 
and high adherence for the first and third tertile, respectively. Logistic regressions were performed 172 
to evaluate the association of each MP and adherence tertiles with PDAC. Time since diagnosis 173 
of morbidities to PDAC diagnosis/recruitment was explored through stratification as recent (<3 174 
years) and long-term (>3 years). Variables whose associations resulted in an OR change >1.5 175 
after stratification by time since diagnosis were combined into a single variable for further analysis. 176 
Interaction between MPs and age, sex, and smoking were calculated comparing models with and 177 
without interaction terms through likelihood ratio test. Additive interactions of morbidities within 178 
each MP were also tested (Supplementary Methods). Excluding patients from Italy did not modify 179 
the results. Heterogeneity by country was not significant (p-value >0.2). Internal validation of 180 
these models was also performed (Supplementary Methods) 181 
Multimorbidity system analysis was performed with DisGeNET (Supplementary 182 
Methods). 183 
 184 
 185 
 186 
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 187 
Results 188 
Demographic and lifestyle information is provided in Supplementary Table S2.  189 
 190 
Individual conditions.  191 
Number of morbidities reported was similar among cases and controls (~7% zero morbidities; 192 
~38% >4 morbidities). When comparing subjects reporting zero morbidities with those reporting 193 
>4, the former were younger (mean age 59 vs. 67 years), less heavy smokers (15.5% vs. 20.1%), 194 
and more commonly males (61.1% vs. 53.3%).  195 
 196 
Comorbidity assessment. 197 
Most morbidities (81%) associated with each other in the same direction in cases and controls, 198 
with only moderate differences (Supplementary Figure 1). Nine comorbidities and four 199 
trimorbidities were significantly associated with PDAC after multiple test correction 200 
(Supplementary Table S4). The strongest positive association was observed for “T2DM and acid 201 
regurgitation” (OR, 4.25; 95%CI, 2.55-7.08). The average SPP for these associations was 93.3, 202 
i.e. if the analysis were repeated 100 times the association would be statistically significant 93 203 
times after multiple test correction. Significant trimorbidities (average SPP, 93.4) always included 204 
T2DM and a combination of other conditions with ORs around 4, suggesting that the association 205 
of T2DM with PDAC risk might be potentiated by some morbidities. 206 
 207 
Multimorbidity assessment.  208 
Three clear patterns of conditions emerged: 1) Gastric:  heartburn, acid regurgitation, H. pylori, 209 
and ulcer; 2) MetS: obesity, T2DM, hypercholesterolemia and hypertension; and 3) Atopic: nasal 210 
allergies, skin allergies and asthma (Figure 1). The remaining conditions did not follow a 211 
consistent pattern of co-occurrence and were not considered in further analyses. 212 
A positive association was observed between PDAC risk and the gastric and MetS 213 
patterns with a positive trend (p-value <0.01); a negative association was observed in the atopic 214 
pattern (Table 1). Similar findings were observed when comparing the highest with the lowest 215 
adherence tertiles. An interaction was observed between MetS and sex; >3 MetS conditions was 216 
associated with PDAC in males but not in females (p-value = 0.032, Supplementary Table S5).  217 
 218 
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Time since diagnosis. 219 
Associations do not necessarily indicate causality; therefore, we assessed the 220 
associations  in relation to the period since diagnosis of conditions and PDAC.  Recent diagnosis 221 
of the gastric pattern showed stronger association with PDAC risk than long-term diagnosis (OR 222 
and 95%CI: 6.13, 3.01-12.5; 1.17, 0.79-1.73; respectively). Stratification of the MetS pattern was 223 
done based of T2DM diagnosis because the other conditions did not show different associations 224 
with PDAC by time since diagnosis: OR, 1.61; 95%CI, 1.11-2.35 for recent and OR, 1.35; 95%CI, 225 
0.99-1.85 for long-term diagnosis. This analysis could not be performed for the atopic pattern 226 
because time since diagnosis was only available for asthma. 227 
 Gastric MP and T2DM showed the greatest change in their association with PDAC after 228 
stratification by time since diagnosis (Supplementary Table S3). Considered altogether, having 229 
>1 of these was strongly associated with PDAC among subjects with recent diagnosis (OR, 7.89; 230 
95%CI, 3.9-16.1 for >2 conditions) while a moderate estimate was observed among subjects with 231 
long-term diagnosis (OR, 1.86; 95%CI, 1.29-2.67 for >3 conditions, Table 2). The average AUC 232 
for this model was 0.78 (SD= 0.011) for recently diagnosed conditions; and 0.72 (SD= 0.01) and 233 
0.74 (SD= 0.009) for long-term and lifetime models, respectively (data not shown). Treating 234 
obesity as a confounder showed similar results (Supplementary Table S6).  235 
Bioinformatics analysis showed a stronger genetic link among morbidities included in the 236 
metabolic and atopic patterns in comparison to those of the gastric pattern, possibly due to less 237 
reported disease-gene associations in the latter. All patterns shared genetic links with PDAC 238 
(Supplementary Figure S2), and many of these conditions shared inflammatory related genes 239 
such as TNF, CXCL8, HIF1A, and PTGS2 (Supplementary Figure S3).  240 
 241 
Discussion 242 
We analyzed the aggregation and association of 17 self-reported medical conditions with PDAC 243 
risk in a large case-control European study. We identified three MPs: the gastric and MetS 244 
patterns, positively associated with PDAC, and the atopic pattern, negatively associated. 245 
Moreover, we explored MPs in the temporal context of pancreatic cancer which provides clues 246 
about common mechanisms and causal effect. 247 
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Among the gastric pattern, sensitivity analysis showed that heartburn and acid 248 
regurgitation had the strongest effect on the association. In the MetS pattern, T2DM was the main 249 
driving condition since removing T2DM from the pattern resulted in loss of significance. In the 250 
atopic pattern, none of the conditions seemed to drive the association individually.  251 
 Associations between gastric and MetS patterns with PDAC were significant only among 252 
subjects with recently diagnosed conditions. Our results strengthen previous findings with smaller 253 
case sample size or pooled heterogeneous populations reporting positive associations between 254 
history of gastric or duodenal ulcer with PDAC only among recently diagnosed subjects [2, 13, 255 
14]. Two cohort studies reported a significant association between PDAC and long-term diagnosis 256 
(up to 20 years) of gastric but not duodenal ulcer [15, 16]; whether gastric ulcer was related to H. 257 
pylori infection was not elucidated. A recent meta-analysis including ten case-control studies 258 
reported a non-significant association between overall H. pylori infection and PDAC [17]. These 259 
studies did not consider time since diagnosis and are limited in their ability to assess causality. 260 
Less information exists for acid regurgitation or heartburn. One study reported a significant 261 
positive association between PDAC and episodes of >4 weeks of heartburn up to 5 years prior to 262 
cancer diagnosis/interview [18]. For the MetS pattern, this observation was attributed to T2DM 263 
confirming and extending previous reports of a stronger positive association among new-onset 264 
diabetics [4, 19]. Importantly, the significant association between three or more MetS conditions 265 
and PDAC was restricted to males, pointing to a potential role of BMI since, contrary to females, 266 
there were more obese males among cases (22.6%) than controls (18.9%). Previous studies 267 
reported contradictory results on the interaction between MetS and sex [7, 8, 11, 12], more studies 268 
are needed to confirm our observations. Although recent asthma diagnosis was reported by <1%, 269 
long-term asthmatics were negatively associated with PDAC. Consistently, a significant inverse 270 
association between PDAC and nasal allergies unrelated to disease duration has been reported 271 
[20].  272 
 Five conditions (i.e. T2DM and gastric conditions) stood out by the magnitude of OR 273 
change after stratification by time since diagnosis. When consolidated into a single variable, a 274 
stronger positive association was observed between having >1 of these conditions recently 275 
diagnosed and PDAC. T2DM was an important driver of this association, but having >3 of these 276 
conditions showed a stronger estimate than by T2DM alone highlighting the potential significance 277 
of combining morbidities when studying PDAC. Bootstrapped AUCs showed a fair performance 278 
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of the models including these five conditions; restriction to recent diagnosis resulted in the best 279 
performance. Conceivably, additive interactions between morbidities within MPs could explain 280 
these results. In this regard we observed a significant additive interaction between asthma and 281 
both nasal and skin allergies, and a significant sub-additive interaction between diabetes and the 282 
combination of any three or more gastric conditions; however, we were limited by sample size in 283 
these analyses. Mechanistically, these associations might be explained in the context of systemic 284 
inflammation: early events during PDAC carcinogenesis could favor the development of type 3c 285 
diabetes, altogether prompting dysbiosis which could, in turn, be manifested as gastric conditions. 286 
Further analysis showed an intricate genetic system among the MPs and pancreatic cancer 287 
pointing to a potential mechanistic link between these (Supplementary Figure S2 and S3).  288 
It has been hypothesized that PDAC development might occur during the ten years 289 
previous to its detection with disease manifestations in the preceding 1-2 years. Yet, there are 290 
arguments in favor of a rapid "catastrophic" evolution shortly before diagnosis [21]. We aimed at 291 
discriminating medical conditions acting as true risk/protective factors (long-term diagnosis) vs. 292 
early manifestations of PDAC (recent diagnosis). We show that long-term T2DM and asthma are 293 
associated with PDAC, pointing to them as true risk and protective factors, respectively. 294 
Interestingly, the co-occurrence of long-term T2DM with long-term gastric conditions was 295 
associated with a stronger PDAC risk than that conferred by T2DM alone indicating that while 296 
T2DM is a main risk factor of PDAC, its overlap with other gastric conditions might further 297 
aggravate carcinogenesis. We also provide strong evidence that several conditions associate with 298 
PDAC risk only when diagnosed shortly before PDAC, suggesting that these could be PDAC 299 
manifestations. This concept has been discussed in the context of T2DM [4, 13, 19, 22, 23], and 300 
it is further supported by studies showing improvement of insulin resistance and glucose 301 
intolerance after PDAC resection [24, 25]. However, we cannot rule out that pathophysiologically 302 
distinct subtypes of T2DM and/or other conditions might accelerate PDAC progression resulting 303 
in a shorter time between diagnoses.  304 
Early PDAC diagnosis provides the only opportunity for long-term survival. Establishing 305 
a set of conditions alerting the clinical staff of potential PDAC cases could improve diagnosis, 306 
management and/or treatment of patients and consequently, the outcome of the disease. 307 
However, the symptoms/conditions here described are relatively non-specific hindering their 308 
immediate adscription to PDAC. Moreover, whether PDAC stage at diagnosis modifies the 309 
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reported associations deserves further investigation.  While innovative and detailed analyses 310 
have been performed to both identify MPs and to assess their risk with PDAC, bias by 311 
unmeasured confounders is always a concern (i.e., metformin or statins medications have been 312 
associated with decreased risk of PDAC). Future studies should focus on exploring the role of 313 
particular treatments in these associations.  314 
Our study has some limitations. The information was self-reported thus, misclassification 315 
and bias cannot be completely ruled out; nevertheless, the consistency of basic findings in this 316 
report with existing literature argues against this possibility. Our study is one of the largest 317 
performed but - despite its size and the restriction of our analyses to conditions with a frequency 318 
>2% in cases and controls – statistical power remains an issue when considering multimorbidities 319 
and stratification by time since diagnosis. 320 
To our knowledge, this is the first study that simultaneously considers the association of 321 
many morbidities with PDAC. We report three main MPs significantly associated with PDAC and 322 
show that the associations change depending on the time since diagnosis of morbidities. Owing 323 
the high prevalence of multimorbidities, evaluating MPs may help to improve the characterization 324 
of PDAC risk. Confirmation of these results in independent studies will be critical in their 325 
generalization and future clinical application. Identification of early manifestations of PDAC may 326 
help define subpopulations of patients in whom screening might be cost-effective [26]. Moreover, 327 
the discovery of risk and protective associations should lead to more pathophysiological studies. 328 
Thus, the knowledge generated could contribute to implement novel preventive and therapeutic 329 
strategies.  330 
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Supplementary Annex. PanGenEU centres and investigators (1 Principal Investigator in each 425 
centre) 426 
Spanish National Cancer Research Centre (CNIO), Madrid, Spain: Núria Malats1, Francisco X 
Real1, Mirari Marquez, Roger Milne, Paulina Gómez, Ana Sagrera. 
Verona University, Italy: Aldo Scarpa1, Rita Lawlor, Giada Bonizzato, Sonia Grimaldi. 
National Cancer Registry Ireland, Cork, Ireland: Linda Sharp1, Damian O’Driscoll. 
Hospital Madrid-Norte-Sanchinarro, Madrid, Spain: Manuel Hidalgo1. 
Hospital Ramon y Cajal, Madrid, Spain: Alfredo Carrato1, Carmen Guillén-Ponce. 
Hospital del Mar, Barcelona, Spain: Lucas Ilzarbe1, Cristina Álvarez-Urturi, Xavier Bessa, 
Felipe Bory, Lucía Márquez Mosquera, Ignasi Poves Prim, Fernando Burdío, Luis Grande, Mar 
Iglesias, Javier Gimeno. 
Hospital Vall d´Hebron, Barcelona, Spain: Xavier Molero1, Luisa Guarner, Joaquin Balcells. 
Technical University of Munich, Germany: Christoph Michalski1, Jörg Kleeff, Bo Kong 
Karolinska Institute, Stockholm, Sweden: Matthias Löhr1, Jiaqui Huang. 
Hospital 12 de Octubre, Madrid, Spain: José Perea1, Pablo Peláez. 
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain: Antoni Farré1, Josefina Mora, Marta 
Martín, Vicenç Artigas, Carlos Guarner Argente, Francesc J Sancho, Mar Concepción, Teresa 
Ramón y Cajal. 
The Royal Liverpool University Hospital, UK: William Greenhalf1, Eithne Costello. 
Queen’s University Belfast, UK: Liam Murray1, Michael O’Rorke, Marie Cantwell. 
Laboratorio de Genética Molecular, Hospital General Universitario de Elche, Spain: Víctor M 
Barberá1, Javier Gallego. 
Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain: Adonina 
Tardón1, Luis Barneo. 
Hospital Clínico Universitario de Santiago de Compostela, Spain: Enrique Domínguez Muñoz1, 
Antonio Lozano, Maria Luaces. 
Hospital Clínico Universitario de Salamanca, Spain: Luís Muñoz-Bellvís1, J.M. Sayagués 
Manzano, M.L. Gutíerrrez Troncoso, A. Orfao de Matos. 
University of Marburg, Department of Gastroenterology, Phillips University of Marburg, 
Germany: Thomas Gress1, Malte Buchholz, Albrecht Neesse. 
Queen Mary University of London, UK: Tatjana Crnogorac-Jurcevic1, Hemant M Kocher, 
Satyajit Bhattacharya, Ajit T Abraham, Darren Ennis, Thomas Dowe, Tomasz Radon 
Scientific advisors of the PanGenEU Study: Debra T Silverman (NCI, USA) and Douglas 
Easton (U. of Cambridge, UK) 
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 430 
Figure Legends 431 
 432 
Figure 1. Clustering of morbidities in pancreatic ductal adenocarcinoma cases and 433 
controls. A) Dendrogram depicting Hierarchical cluster analysis using Yule’s Q distance matrix, 434 
B) Loadings from principal component analysis, C) Loadings from factor analysis. Loadings >0.3 435 
are considered to belong to the same component and factor, respectively. Yule’s Q distance was 436 
calculated as (1 - ((ad-bc)/(ad+bc))), where a indicates presence of both conditions, b and d 437 
absence of one condition and presence of the other, and d absence of both conditions. 438 
PanGenEU, 2009-2014. 439 
 440 
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